利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

1225 条记录 (耗时 0.036 秒)

    Insulin receptor substrate 1 (IRS1) protein SRM/MRM assay
    62.
    发明授权
    Insulin receptor substrate 1 (IRS1) protein SRM/MRM assay 有权
    胰岛素受体底物1（IRS1）蛋白SRM / MRM测定

    公开(公告)号：US09417246B2

    公开(公告)日：2016-08-16

    申请号：US13529902

    申请日：2012-06-21

    申请人： David B. Krizman ,  Todd Hembrough ,  Sheeno Thyparambil

    发明人： David B. Krizman ,  Todd Hembrough ,  Sheeno Thyparambil

    IPC分类号： C12Q1/37 ,  G01N33/68

    CPC分类号： G01N33/57496 ,  G01N33/574 ,  G01N33/6848 ,  G01N2333/4703 ,  G01N2333/62 ,  G01N2333/72 ,  G01N2440/14 ,  G01N2440/38 ,  G01N2560/00 ,  G01N2800/52

    摘要： The current disclosure provides for specific peptides from the Insulin Receptor Substrate 1 (IRS1) protein and the derived ionization characteristics of those peptides that are advantageous for quantifying IRS1 directly in formalin fixed biological samples by the method of Selected Reaction Monitoring (SRM) mass spectrometry. Such fixed biological samples include: formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and formalin fixed and paraffin embedded tissue culture cells. IRS1 protein is quantitated in biological samples by the method of SRM/MRM mass spectrometry by quantitating one or more of the peptides described herein. The peptides can be quantitated if they reside in a modified or an unmodified form. Examples of potentially modified forms of IRS1 peptides include those bearing phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence.

    摘要翻译： 目前的公开内容提供了来自胰岛素受体底物1（IRS1）蛋白的特异性肽和这些肽的衍生电离特征，其有利于通过选择反应监测（SRM）质谱法直接定量福尔马林固定生物样品中的IRS1。 这样的固定生物样品包括：福尔马林固定的组织/细胞，福尔马林固定/石蜡包埋（FFPE）组织/细胞，FFPE组织块和来自那些块的细胞，以及福尔马林固定和石蜡包埋的组织培养细胞。 通过定量本文所述的一种或多种肽，通过SRM / MRM质谱法测定生物样品中的IRS1蛋白质。 如果它们以修饰或未修饰的形式存在，则可定量肽。 IRS1肽的潜在修饰形式的实例包括在肽序列内具有酪氨酸，苏氨酸，丝氨酸和/或其它氨基酸残基磷酸化的那些。

    Methods of treating alzheimer's disease by administration of protective protein/cathepsin A
    63.
    发明授权
    Methods of treating alzheimer's disease by administration of protective protein/cathepsin A 有权
    通过给予保护性蛋白/组织蛋白酶治疗阿尔茨海默病的方法A

    公开(公告)号：US09399791B2

    公开(公告)日：2016-07-26

    申请号：US14239728

    申请日：2012-08-28

    申请人： Ida Annunziata ,  Alessandra D'Azzo

    发明人： Ida Annunziata ,  Alessandra D'Azzo

    IPC分类号： A61K38/47 ,  C12Q1/34 ,  G01N33/574 ,  A61K38/48 ,  G06F19/00

    CPC分类号： C12Q1/34 ,  A61K38/47 ,  A61K38/48 ,  A61K38/4813 ,  C12Y302/01018 ,  G01N33/573 ,  G01N33/57484 ,  G01N33/57496 ,  G01N2333/924 ,  G01N2800/2821 ,  G01N2800/56 ,  G06F19/00 ,  G06F19/34

    摘要： Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile. As such, the level of lysosomal exocytosis activity and/or lysosomal sialidase activity is predictive of a diagnosis and/or prognosis of cancer, chemotherapy resistance or dementia associated with Alzheimer's disease.

    摘要翻译： 提供了各种病理状态的预后，诊断和治疗方法，包括与阿尔茨海默氏病有关的癌症，耐化学药物和痴呆症。 本文提供的方法基于以下发现：具有高水平唾液酸化的各种蛋白质在本文中显示为与疾病状态相关，例如与阿尔茨海默氏病相关的癌症，化疗耐药性和痴呆。 这样的方法提供了包含一个或多个代表溶酶体胞吐作用活性的值的溶酶体胞吐活性谱。 这里也提供了低溶酶体唾液酸酶活性与各种病理状态相关的发现。 因此，所述方法还提供溶酶体唾液酸酶活性谱，其包含一个或多个表示溶酶体唾液酸酶活性的值。 溶酶体唾液酸酶活性谱是溶酶体胞吐活性谱的一个实例。 因此，溶酶体胞吐作用和/或溶酶体唾液酸酶活性的水平预示着与阿尔茨海默氏病相关的癌症，耐化学药物或痴呆症的诊断和/或预后。

    Monoclonal antibody against necrosis marker ERP29 and use thereof
    65.
    发明授权
    Monoclonal antibody against necrosis marker ERP29 and use thereof 有权
    针对坏死标记物ERP29的单克隆抗体及其用途

    公开(公告)号：US09377461B2

    公开(公告)日：2016-06-28

    申请号：US13583312

    申请日：2011-03-08

    申请人： Sumio Sugano ,  Yukari Kanzaki ,  Tsuneo Saga ,  Atsushi Tsuji

    发明人： Sumio Sugano ,  Yukari Kanzaki ,  Tsuneo Saga ,  Atsushi Tsuji

    IPC分类号： C07K16/00 ,  C12P21/08 ,  G01N33/574 ,  A61K51/10 ,  C07K16/30 ,  C07K16/18

    CPC分类号： G01N33/574 ,  A61K51/1045 ,  A61K51/1093 ,  C07K16/18 ,  C07K16/30 ,  C07K2317/14 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/57496 ,  G01N2333/47 ,  G01N2333/908 ,  G01N2800/00

    摘要： [PROBLEM] To provide a monoclonal antibody against a biomarker which shows high specificity and can be effectively used in detection and diagnosis of various lesions relevant to various kinds of carcinomas and foci of necrosis, and so forth.[MEANS] A monoclonal antibody against a necrosis marker consisting the following amino acid sequence: (1) the amino acid sequence of any of SEQ ID NOs: 1 to 3, or (2) an amino acid sequence having substitution, deletion and/or insertion of one or several amino acid residues in the amino acid sequence of (1) or sharing a homology of 90% or more with the amino acid sequence of (1), and showing the same function, activity or property as that of the amino acid sequence of (1) as a protein.

    摘要翻译： 提供针对生物标志物的单克隆抗体，其显示高特异性并且可以有效地用于检测和诊断与各种癌症和坏死灶相关的各种损伤等。 构成下列氨基酸序列的抗坏血酸标记单克隆抗体：（1）SEQ ID NO：1〜3中任一项所述的氨基酸序列，或（2）具有取代，缺失和/或缺失的氨基酸序列 在（1）的氨基酸序列中插入一个或几个氨基酸残基或与（1）的氨基酸序列共享90％以上的同源性，并显示与氨基酸的氨基酸序列相同的功能，活性或性质 （1）的酸序列作为蛋白质。

    Biomarkers of Response to Inhibition of Poly-ADP Ribose Polymerase (PARP) in Cancer
    67.
    发明申请
    Biomarkers of Response to Inhibition of Poly-ADP Ribose Polymerase (PARP) in Cancer 审中-公开
    生物标志物对癌症中多聚ADP核糖聚合酶（PARP）的抑制作用

    公开(公告)号：US20160138114A1

    公开(公告)日：2016-05-19

    申请号：US14899974

    申请日：2014-06-18

    申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

    发明人： Dennis Slamon ,  Richard Finn ,  Dylan Conklin

    IPC分类号： C12Q1/68 ,  G01N33/574 ,  A61K45/06 ,  A61K31/5025

    CPC分类号： C12Q1/6886 ,  A61K31/5025 ,  A61K45/06 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/57496 ,  G01N2333/914

    摘要： Provided herein are methods of identifying a subject having a poly-ADP ribose polymerase (PARP) inhibitor-sensitive tumor by detecting a genomic gain in chromosome 1q21 and/or chromosome 20q13.3 in a tumor sample from the subject. Also provided are methods of identifying a subject having a PARP inhibitor-sensitive tumor by detecting gene amplification of a CHD1L gene or an RTEL1 gene in a tumor sample from the subject. Further provided are methods of treating a tumor with a genomic gain in chromosome 1q21 and/or chromosome 20q13.3 in a subject by administering an effective dose of a PARP inhibitor.

    摘要翻译： 本文提供了通过检测来自受试者的肿瘤样品中的染色体1q21和/或染色体20q13.3中的基因组增益来鉴定具有多聚ADP核糖聚合酶（PARP）抑制剂敏感性肿瘤的受试者的方法。 还提供了通过检测来自受试者的肿瘤样品中CHD1L基因或RTEL1基因的基因扩增来鉴定具有PARP抑制剂敏感性肿瘤的受试者的方法。 还提供了通过施用有效剂量的PARP抑制剂来治疗受试者中染色体1q21和/或染色体20q13.3中的基因组增益的肿瘤的方法。

    METHOD FOR DIAGNOSING CANCER USING SECRETED RIBOSOMAL PROTEIN S3
    68.
    发明申请
    METHOD FOR DIAGNOSING CANCER USING SECRETED RIBOSOMAL PROTEIN S3 审中-公开
    使用分泌型RIBOSOMAL蛋白S3诊断癌症的方法

    公开(公告)号：US20160123986A1

    公开(公告)日：2016-05-05

    申请号：US14590968

    申请日：2015-01-06

    申请人： KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION

    发明人： Joon Kim

    IPC分类号： G01N33/574

    CPC分类号： G01N33/57496 ,  G01N33/574 ,  G01N2333/4703

    摘要： A method for diagnosing cancer using secreted ribosomal protein S3 (rpS3) is described, and more particularly, a method for diagnosing cancer or cancer metastasis using ribosomal protein S3 (rpS3) that is expressed in and secreted from cancer cells. Measuring the amount of extracellularly secreted rpS3 protein according to the present disclosure is highly useful for diagnosing cancer or cancer metastasis in a rapid and convenient manner using a biological sample such as blood.

    摘要翻译： 描述了使用分泌的核糖体蛋白S3（rpS3）诊断癌症的方法，更具体地，涉及使用在癌细胞中表达和分泌的核糖体蛋白S3（rpS3）来诊断癌症或癌症转移的方法。 根据本公开的测量细胞外分泌的rpS3蛋白的量对于使用诸如血液的生物样品以快速和方便的方式诊断癌症或癌症转移是非常有用的。

    ER-stress inducing compounds and methods of use thereof
    70.
    发明授权
    ER-stress inducing compounds and methods of use thereof 有权
    ER应激诱导化合物及其使用方法

    公开(公告)号：US09316631B1

    公开(公告)日：2016-04-19

    申请号：US14057473

    申请日：2013-10-18

    申请人： Whitehead Institute for Biomedical Research

    发明人： Piyush Gupta ,  Yuxiong Feng

    IPC分类号： A61K31/415 ,  A61K31/35 ,  A61K31/41 ,  G01N33/50 ,  G01N33/574 ,  A61K31/4025 ,  A61K31/40

    CPC分类号： G01N33/5011 ,  A61K31/40 ,  A61K31/4025 ,  A61K31/4164 ,  G01N33/57496

    摘要： The invention relates to methods for identifying ER-stress inducing compounds that target cancer stem cells. In some aspects, the invention relates to treatment methods that use ER-stress inducing compounds that specifically target cancer stem cells for inhibiting the growth and/or survival of cancer stem cells in a subject in need thereof. Other aspects of the invention relate to the use of cancer stem cell biomarkers in the selection of a treatment for inhibiting the growth and/or survival of cancer stem cells in a subject in need thereof.

    摘要翻译： 本发明涉及用于鉴定靶向癌症干细胞的ER-应激诱导化合物的方法。 在一些方面，本发明涉及使用特异性靶向癌干细胞的ER应激诱导化合物抑制有需要的受试者的癌干细胞的生长和/或存活的治疗方法。 本发明的其他方面涉及癌症干细胞生物标志物在选择用于抑制有需要的受试者中癌干细胞的生长和/或存活的治疗中的用途。